SB17170 for advanced and metastatic solid tumors
Official title: An Open-label, Multicenter, Phase 1 Clinical Trial to Evaluate MTD, Safety, PK/PD and Preliminary Anti-tumor Activity of SB17170 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Failed Standard of Care
Run by SPARK Biopharma · NCT05522868 · Data updated 2026-11-12
This trial tests SB17170 alone or with standard treatments in adults with advanced or metastatic solid tumors who have exhausted standard options to see if it is safe and shows anti-tumor activity.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | SPARK Biopharma Industry-sponsored |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 3 sites (Seoul and 2 other locations) |
| Status | Recruiting |
| Started | October 17, 2022 |
| Main results expected | June 30, 2027 |
| Study ends | December 30, 2027 |
| Registry record updated | November 20, 2025 |
| Trial ID | NCT05522868 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with histologically confirmed locally advanced or metastatic solid tumors, at least one measurable lesion, ECOG 0–1, who have progressed on or are no longer eligible for standard treatments and are expected to survive at least three months.
✕Probably not a fit
Patients who recently received other systemic cancer therapies within 28 days, who have previously received HMGB1-targeting drugs, or who have poor performance status or very limited life expectancy are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an open-label, multicenter Phase 1 dose-escalation and dose-expansion trial of SB17170 given alone (part 1a) and together with standard-of-care therapies (part 1b) in patients with locally advanced or metastatic solid tumors who have failed available treatments. The study will determine the maximum tolerated dose, safety profile, pharmacokinetics/pharmacodynamics, and collect preliminary evidence of anti-tumor activity. Treatment is given in 21-day cycles with tumor assessments every two cycles. Eligible patients must have measurable disease by RECIST v1.1 and an ECOG performance status of 0 or 1.
Why it matters
Potential benefit: If successful, SB17170 could provide a new treatment option that shrinks tumors or prolongs life for patients who no longer have standard therapies.
How similar studies have gone: Targeting HMGB1 and related pathways is a relatively novel approach with encouraging preclinical data but limited clinical experience to date.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A patient with a histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors. * A person who has failed the known standard of care or has developed resistance to the standard of care and no longer has applicable standard of care * A patient with at least one measurable lesion according to the RECIST v1.1 criteria. * A person with Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1. * Those with an expected survival period of 3 months or more at the discretion of of the investigator. Exclusion Criteria: * A patient who has received drugs targeting High Mobility Group Box 1 (HMGB1). * A patient who has received or is undergoing chemotherapy (including chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted therapy, biological products, and tumor embolization) within 28 days from the first administration date of the investigational drug. * A person who needs to take contraindicated drugs or is expected to take them during the study period.
Where it's running
-
Severance Hospital
Seoul, South Korea Recruiting -
Asan Medical Center
Seoul, South Korea Not yet recruiting -
Seoul National University Hospital
Seoul, South Korea Not yet recruiting
Study contacts
- Study coordinator: Sun Bin Kang
- Email: sbkang@sparkbio.co.kr
- Phone: 8228879905
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
-
SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1
This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.
-
FAPI PET imaging with FAPI-RuiJ and FAPI-04 in solid tumors
This study tests two FAP-targeted PET tracers (FAPI-RuiJ and FAPI-04) to see which better detects, stages, and monitors solid tumors.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
-
SI-B036 in locally advanced or metastatic breast cancer and other solid tumors
Scientists are testing SI-B036 to see if it is safe and tolerable in adults with advanced breast cancer or other solid tumors and to get early signals of whether it might help.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.